Floatz logo

Dkn-01

Carcinosarcoma

Leap Therapeutics, Inc.Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Carcinosarcoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Blueprint Medicines Corporation
Phase 3BB
Ifosfamide
GOG Foundation
Phase 3B
Nivolumab
Instituto do Cancer do Estado de São Paulo
Phase 2CCC
Pamiparib
Australia New Zealand Gynaecological Oncology Group
Phase 2CCC
Carboplatin
Dana-Farber Cancer Institute
Phase 2CCC

View all 12 →

Same molecule, other indications

Dkn-01 is also rated in:

uterine cancerDormant
B
Indicative ·
57 / 100
View asset →
Colo-rectal CancerDormant
B
Indicative ·
57 / 100
View asset →
colorectal adenocarcinomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →